Ranked nationally in pediatric care.
Arkansas Children's provides right-sized care for your child. U.S. News & World Report has ranked Arkansas Children's in seven specialties for 2024-2025.
It's easier than ever to sign up for MyChart.
Sign up online to quickly and easily manage your child's medical information and connect with us whenever you need.
We're focused on improving child health through exceptional patient care, groundbreaking research, continuing education, and outreach and prevention.
When it comes to your child, every emergency is a big deal.
Our ERs are staffed 24/7 with doctors, nurses and staff who know kids best – all trained to deliver right-sized care for your child in a safe environment.
Arkansas Children's provides right-sized care for your child. U.S. News & World Report has ranked Arkansas Children's in seven specialties for 2024-2025.
Looking for resources for your family?
Find health tips, patient stories, and news you can use to champion children.
Support from the comfort of your home.
Our flu resources and education information help parents and families provide effective care at home.
Children are at the center of everything we do.
We are dedicated to caring for children, allowing us to uniquely shape the landscape of pediatric care in Arkansas.
Transforming discovery to care.
Our researchers are driven by their limitless curiosity to discover new and better ways to make these children better today and healthier tomorrow.
We're focused on improving child health through exceptional patient care, groundbreaking research, continuing education, and outreach and prevention.
Then we're looking for you! Work at a place where you can change lives...including your own.
When you give to Arkansas Children's, you help deliver on our promise of a better today and a healthier tomorrow for the children of Arkansas and beyond
Become a volunteer at Arkansas Children's.
The gift of time is one of the most precious gifts you can give. You can make a difference in the life of a sick child.
Join our Grassroots Organization
Support and participate in this advocacy effort on behalf of Arkansas’ youth and our organization.
Learn How We Transform Discovery to Care
Scientific discoveries lead us to new and better ways to care for children.
Learn How We Transform Discovery to Care
Scientific discoveries lead us to new and better ways to care for children.
Learn How We Transform Discovery to Care
Scientific discoveries lead us to new and better ways to care for children.
Learn How We Transform Discovery to Care
Scientific discoveries lead us to new and better ways to care for children.
Learn How We Transform Discovery to Care
Scientific discoveries lead us to new and better ways to care for children.
Learn How We Transform Discovery to Care
Scientific discoveries lead us to new and better ways to care for children.
When you give to Arkansas Children’s, you help deliver on our promise of a better today and a healthier tomorrow for the children of Arkansas and beyond.
Your volunteer efforts are very important to Arkansas Children's. Consider additional ways to help our patients and families.
Join one of our volunteer groups.
There are many ways to get involved to champion children statewide.
Make a positive impact on children through philanthropy.
The generosity of our supporters allows Arkansas Children's to deliver on our promise of making children better today and a healthier tomorrow.
Read and watch heart-warming, inspirational stories from the patients of Arkansas Children’s.
Hello.
Arkansas Children's Hospital
General Information 501-364-1100
Arkansas Children's Northwest
General Information 479-725-6800
As childhood Acute Lymphoblastic Leukemia (ALL) outcomes continue to improve, infants younger than 1 year of age with KMT2A-rearranged (KMT2Ar) ALL remain difficult to cure. Rearrangement of KMT2A characterize a group of high-risk acute leukemias and accounts for approximately 70% to 80% of infantile ALL. While immunotherapy has recently been widely and successfully implemented in ALL, there are unique challenges associated with KMT2Ar-ALL in infants. Thus, effective therapies are still needed.
The goals of this study are to increase disease clearance and sustain deep remission through the use of the immunotherapy agent, blinatumomab. Additionally, this study seeks to determine the minimum safe and effective dose of the menin inhibitor, ziftomenib, when given in combination with chemotherapy at the beginning of treatment for refractory patients.
In addition to a few criteria that could prevent participation, there are criteria participants must meet including but not limited to the following:
Clinicaltrials.gov Study Details >
Contact Information: For more information, contact Ashley Bryan at 501-364-3122 or Suzy Hall at 501-364-4181.